imiquimod has been researched along with paclitaxel in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Heo, MB; Lim, YT; Seth, A | 1 |
| Allison, KH; Childs, JS; Coveler, AL; Dang, Y; Disis, ML; Higgins, DM; Lu, H; Reichow, JL; Salazar, LG; Waisman, J | 1 |
| Cao, X; Cheng, G; Cheng, X; Li, J; Piao, H; Yin, X; Zou, M | 1 |
| Gou, M; Huang, M; Huang, Y; Kang, T; Li, Y; Liu, J; Wang, S; Wang, Y; Wei, X; Xiong, M; Yang, L; Zhu, J | 1 |
| Cheng, G; Jin, S; Liu, W; Mi, R; Pan, W; Piao, H; Zou, M | 1 |
1 trial(s) available for imiquimod and paclitaxel
| Article | Year |
|---|---|
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Aged; Aged, 80 and over; Albumins; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Humans; Imiquimod; Lymphocytes, Tumor-Infiltrating; Middle Aged; Monocytes; Paclitaxel; Programmed Cell Death 1 Receptor; Salvage Therapy; Skin Neoplasms; Treatment Outcome | 2017 |
5 other study(ies) available for imiquimod and paclitaxel
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Survival; Dendritic Cells; Female; Humans; Imiquimod; Lymph Nodes; Macrophages; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Paclitaxel; Particle Size; Polyglutamic Acid; Solubility; Survival Analysis; Toll-Like Receptor 7; Tumor Burden; Water | 2014 |
A Novel Surfactant-Free O/O Paclitaxel Ointment for the Topical Treatment of Psoriasis.
Topics: Administration, Topical; Animals; Humans; Imiquimod; Male; Mice; Mice, Inbred BALB C; Ointments; Paclitaxel; Particle Size; Psoriasis; Skin; Surface-Active Agents | 2019 |
Modular Engineering of Targeted Dual-Drug Nanoassemblies for Cancer Chemoimmunotherapy.
Topics: Animals; Antigen Presentation; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Drug Therapy; Female; Imiquimod; Immunotherapy; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Rats, Sprague-Dawley; Tissue Distribution | 2019 |
Tacrolimus and paclitaxel co-loaded O/O ointment without surfactant: Synergistic combinations for the treatment of psoriasis.
Topics: Humans; Imiquimod; Ointments; Paclitaxel; Psoriasis; Pulmonary Surfactants; Surface-Active Agents; Tacrolimus | 2023 |